Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 2, 2009CancerOpen Access

Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMarc PeetersAstraZeneca (United Kingdom)
Salvatore Siena
Salvatore SienaInstitució Catalana de Recerca i Estudis Avançats
Eric Van Cutsem
Eric Van CutsemKU Leuven

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Peeters et al. (2009) studied this question.

synapsesocial.com/papers/69dabb094a1e15904c835f35https://doi.org/10.1002/cncr.24088
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer2000 · 3,834 citations
  2. 2Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer2004 · 5,068 citations
  3. 3Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?2005 · 490 citations
  4. 4What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN)2003 · 108 citations
  5. 5Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer2007 · 1,999 citations